EU CCP Database – Covid-19 convalescent plasma collection and transfusion in the EU The European Commission is working together with Member States, the European Blood Alliance (EBA), the European Centre for Disease Prevention and Control (ECDC) and other health professionals to support a study of convalescent plasma as a treatment for COVID-19 patients. The study complements the guidance issued
A high cumulative incidence of thrombotic complications was reported in critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three Dutch hospitals. The incidence was re-evaluated of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction and/or systemic arterial embolism in all COVID-19 patients admitted
Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow. A group of US academic researchers has sparked a nationwide effort to encourage people who have recovered from COVID-19 to donate plasma, which will be used to treat patients across
NETs played a pivotal role in the hypercoagulability of stroke patients. Strategies that prevent NET formation may offer a potential therapeutic strategy for thromboembolism interventions in Covid-19 patients. Sivelestat, anti-MMP9 antibody, and APC inhibit the cytotoxic effects of NET to protect ECs and decrease PCA, suggesting their critical role in preventing thrombotic complications in atherosclerosis
Using the Lionheart™ FX to Image and Analyze Stimulated dHL60 Cells Abstract Neutrophils play a key role in the body’s defense against infections. As part of the innate immune system, they employ multiple strategies to degrade and kill microbes, including the release of neutrophil extracellular traps (NETs). NETs are a web-like structure composed of antimicrobial
An extensive overview of convalescent plasma therapeutic use in Covid-19 has just been published on JAMA 30 April. The analysed points are the following: need of randomised controlled trials: Without randomized controlled trials, researchers can’t be sure whether patients recovered because of an experimental therapy or in spite of it. Yet virtually everything that’s known
Business in every sector is becoming increasingly concerned about the impact of COVID-19, according to the CoRisk-Index, a new online tool from the University of Oxford. The Index is the first economic indicator of industry-specific risk assessments related to the pandemic. Preliminary findings suggest sectors, such as manufacturing and retail, report strong exposure to supply and demand
A new study led by researchers at Oxford and Guangdong Centre for Diseases Control and Prevention describes the epidemiology and genetic make-up of the COVID-19 outbreak in China’s most populous region, and shows how early and intensive testing and tracing helped to interrupt local transmission of the virus. The study combines genome sequencing and epidemiology
A third of patients admitted to hospital with covid-19 in the UK died—putting the fatality rate on a par with Ebola—according to a study which tracked the outcomes of 16 749 patients. The study—the largest detailed description of covid-19 in Europe—found that being obese, male, or elderly reduces chance of survival. The research was carried out
The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratorydisease, has infected over 2.3 million people, killed over 160,000, and causedworldwide social and economic disruption.There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2
